Gene therapy with an improved doxycycline-regulated plasmid encoding a tumour necrosis factor-alpha inhibitor in experimental arthritis

Arthritis Research and Therapy

Volumn 9, Issue , 2007, Pages

  Gould, David ^a   Yousaf, Nasim ^a   Fatah, Rewas ^a   Subang, Maria Cristina ^a   Chernajovsky, Yuti ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; DOXYCYCLINE; LUCIFERASE; PLASMID VECTOR; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; ELECTROPORATION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; ANIMAL; CELL STRAIN COS1; CERCOPITHECUS; COMPARATIVE STUDY; DBA MOUSE; DRUG ANTAGONISM; GENE THERAPY; GENE VECTOR; GENETICS; METHODOLOGY; PLASMID;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CERCOPITHECUS AETHIOPS; COS CELLS; DOXYCYCLINE; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED DBA; PLASMIDS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33847251554     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2113     Document Type: Article

References (50)

1. Moreland LW Schiff MH Baumgartner SW Tindall EA Fleischmann RM Bulpitt KJ Weaver AL Keystone EC Furst DE Mease PJ Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial Ann Intern Med 1999 130 478-486 10075615
2. Wolff JA Malone RW Williams P Chong W Acsadi G Jani A Felgner PL Direct gene transfer into mouse muscle in vivo Science 1990 247 1465-1468 10.1126/science.1690918 1690918
3. Isner JM Baumgartner I Rauh G Schainfeld R Blair R Manor O Razvi S Symes JF Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results J Vasc Surg 1998 28 964 973 discussion 73-75 10.1016/S0741-5214(98)70022-9 9845647
4. Baumgartner I Pieczek A Manor O Blair R Kearney M Walsh K Isner JM Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia Circulation 1998 97 1114-1123 9537336
5. Mir LM Bureau MF Gehl J Rangara R Rouy D Caillaud JM Delaere P Branellec D Schwartz B Scherman D High-efficiency gene transfer into skeletal muscle mediated by electric pulses Proc Natl Acad Sci USA 1999 96 4262-4267 16320 10200250 10.1073/pnas.96.8.4262
6. Pinals RS Baum J Bland J Fosdick WM Kaplan SB Masi AT Mitchell DM Ropes MW Short CL Sigler JW Weinberger HJ Preliminary criteria for clinical remission in rheumatoid arthritis Bull Rheum Dis 1982 32 7-10 7093570
7. Gossen M Bujard H Tight control of gene expression in mammalian cells by tetracycline-responsive promoters Proc Natl Acad Sci USA 1992 89 5547-5551 49329 1319065 10.1073/pnas.89.12.5547
8. Gossen M Freundlieb S Bender G Muller G Hillen W Bujard H Transcriptional activation by tetracyclines in mammalian cells Science 1995 268 1766-1769 10.1126/science.7792603 7792603
9. Watsuji T Okamoto Y Emi N Katsuoka Y Hagiwara M Controlled gene expression with a reverse tetracycline-regulated retroviral vector (RTRV) system Biochem Biophys Res Com 1997 234 769-773 10.1006/ bbrc.1997.6705 9175791
10. Strathdee CA McLeod MR Hall JR Efficient control of tetracycline-responsive gene expression from an autoregulated bi-directional expression vector Gene 1999 229 21-29 10.1016/ S0378-1119(99)00045-1 10095100
11. Gould DJ Berenstein M Dreja H Ledda F Podhajcer OL Chernajovsky Y A novel doxycycline inducible autoregulatory plasmid which displays "on"/"off" regulation suited to gene therapy applications Gene Ther 2000 7 2061-2070 10.1038/sj.gt.3301354 11223986
12. Forster K Helbl V Lederer T Urlinger S Wittenburg N Hillen W Tetracycline-inducible expression systems with reduced basal activity in mammalian cells Nucleic Acids Res 1999 27 708-710 148237 9863002 10.1093/ nar/27.2.708
13. Urlinger S Baron U Thellmann M Hasan MT Bujard H Hillen W Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity Proc Natl Acad Sci USA 2000 97 7963-7968 16653 10859354 10.1073/pnas.130192197
14. Salucci V Scarito A Aurisicchio L Lamartina S Nicolaus G Giampaoli S Gonzalez-Paz O Toniatti C Bujard H Hillen W Tight control of gene expression by a helper-dependent adenovirus vector carrying the rtTA2(s)-M2 tetracycline transactivator and repressor system Gene Ther 2002 9 1415-1421 10.1038/sj.gt.3301813 12378403
15. Lamartina S Silvi L Roscilli G Casimiro D Simon AJ Davies ME Shiver JW Rinaudo CD Zampaglione I Fattori E Construction of an rtTA2(s)-m2/ tts(kid)-based transcription regulatory switch that displays no basal activity, good inducibility, and high responsiveness to doxycycline in mice and non-human primates Mol Ther 2003 7 271-280 10.1016/ S1525-0016(02)00051-5 12597916
16. Barde I Zanta-Boussif MA Paisant S Leboeuf M Rameau P Delenda C Danos O Efficient control of gene expression in the hematopoietic system using a single Tet-on inducible lentiviral vector Mol Ther 2006 13 382-390 10.1016/j.ymthe.2005.09.012 16275162
17. Neve R Kissonerghis M Clark J Feldmann M Chernajovsky Y Expression of an efficient small molecular weight tumour necrosis factor/lymphotoxin antagonist Cytokine 1996 8 365-370 10.1006/cyto.1996.0050 8726664
18. Triantaphyllopoulos K Croxford J Baker D Chernajovsky Y Cloning and expression of murine IFN beta and a TNF antagonist for gene therapy of experimental allergic encephalomyelitis Gene Ther 1998 5 253-263 10.1038/ sj.gt.3300570 9578846
19. Gould DJ Bright C Chernajovsky Y Inhibition of established collagen-induced arthritis with a tumour necrosis factor-alpha inhibitor expressed from a self-contained doxycycline regulated plasmid Arthritis Res Ther 2004 6 R103-113 400428 15059273 10.1186/ar1036
20. Yousaf N Gould DJ Aganna E Hammond L Mirakian RM Turner MD Hitman GA McDermott MF Chernajovsky Y Tumor necrosis factor receptor I from patients with tumor necrosis factor receptor-associated periodic syndrome interacts with wild-type tumor necrosis factor receptor I and induces ligand-independent NF-kappaB activation Arthritis Rheum 2005 52 2906-2916 10.1002/art.21268 16142754
21. Caccese RG Zimmerman JL Carlson RP Bacterial lipopolysaccharide potentiates type II collagen-induced arthritis in mice Mediators Inflamm 1992 1 273-279
22. Feldmann M Maini RN Anti-TNF alpha therapy of rheumatoid arthritis: What have we learned? Annu Rev Immunol 2001 19 163-196 10.1146/ annurev.immunol.19.1.163 11244034
23. Ghosh S Anti-TNF therapy in Crohn's disease Novartis Found Symp 2004 263 193-205 discussion 205-218 15669643
24. Howarth PH Babu KS Arshad HS Lau L Buckley M McConnell W Beckett P Al Ali M Chauhan A Wilson SJ Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma Thorax 2005 60 1012-1018 10.1136/thx.2005.045260 16166100
25. Szlosarek PW Balkwill FR Tumour necrosis factor alpha: A potential target for the therapy of solid tumours Lancet Oncol 2003 4 565-573 10.1016/S1470-2045(03)01196-3 12965278
26. Urrutia R KRAB-containing zinc-finger repressor proteins Genome Biol 2003 4 231 328446 14519192 10.1186/gb-2003-4-10-231
27. Deuschle U Meyer WK Thiesen HJ Tetracycline-reversible silencing of eukaryotic promoters Mol Cell Biol 1995 15 1907-1914 230416 7891684
28. Mizuguchi H Xu Z Ishii-Watabe A Uchida E Hayakawa T IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector Mol Ther 2000 1 376-382 10.1006/ mthe.2000.0050 10933956
29. Howe JR Skryabin BV Belcher SM Zerillo CA Schmauss C The responsiveness of a tetracycline-sensitive expression system differs in different cell lines J Biol Chem 1995 270 14168-14174 10.1074/jbc.270.23.14168 7775477
30. Gould DJ Chernajovsky Y Endogenous GATA factors bind the core sequence of the tetO and influence gene regulation with the tetracycline system Mol Ther 2004 10 127-138 10.1016/j.ymthe.2004.04.011 15233949
31. Bestor TH Gene silencing as a threat to the success of gene therapy J Clin Invest 2000 105 409-411 289175 10683368
32. Brooks AR Harkins RN Wang P Qian HS Liu P Rubanyi GM Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle J Gene Med 2004 6 395-404 10.1002/jgm.516 15079814
33. Jenke AC Scinteie MF Stehle IM Lipps HJ Expression of a transgene encoded on a non-viral episomal vector is not subject to epigenetic silencing by cytosine methylation Mol Biol Rep 2004 31 85-90 10.1023/ B:MOLE.0000031363.35839.46 15293783
34. Davis HL Whalen RG Demeneix BA Direct gene transfer into skeletal muscle in vivo: Factors affecting efficiency of transfer and stability of expression Hum Gene Ther 1993 4 151-159 8494924
35. Sternberg EA Spizz G Perry WM Vizard D Weil T Olson EN Identification of upstream and intragenic regulatory elements that confer cell-type-restricted and differentiation-specific expression on the muscle creatine kinase gene Mol Cell Biol 1988 8 2896-2909 363509 3405222
36. Cao B Bruder J Kovesdi I Huard J Muscle stem cells can act as antigen-presenting cells: Implication for gene therapy Gene Ther 2004 11 1321-1330 10.1038/sj.gt.3302293 15175641
37. Weeratna RD Wu T Efler SM Zhang L Davis HL Designing gene therapy vectors: Avoiding immune responses by using tissue-specific promoters Gene Ther 2001 8 1872-1878 10.1038/sj.gt.3301602 11821941
38. Williams RO Feldmann M Maini RN Antitumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis Proc Natl Acad Sci USA 1992 89 9784-9788 50217 1409699 10.1073/pnas.89.20.9784
39. Joosten LA Helsen MM van de Loo FA van den Berg WB Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra Arthritis Rheum 1996 39 797-809 10.1002/art.1780390513 8639177
40. Bloquel C Bessis N Boissier MC Scherman D Bigey P Gene therapy of collagen-induced arthritis by electrotransfer of human tumor necrosis factor-alpha soluble receptor I variants Hum Gene Ther 2004 15 189-201 10.1089/104303404772679995 14975191
41. Kim JM Ho SH Hahn W Jeong JG Park EJ Lee HJ Yu SS Lee CS Lee YW Kim S Electro-gene therapy of collagen-induced arthritis by using an expression plasmid for the soluble p75 tumor necrosis factor receptor-Fc fusion protein Gene Ther 2003 10 1216-1224 10.1038/sj.gt.3301985 12858186
42. Jiao S Williams P Berg RK Hodgeman BA Liu L Repetto G Wolff JA Direct gene transfer into nonhuman primate myofibers in vivo Hum Gene Ther 1992 3 21-33 1532913
43. Hagstrom JE Hegge J Zhang G Noble M Budker V Lewis DL Herweijer H Wolff JA A facile nonviral method for delivering genes and siRNAs to skeletal muscle of mammalian limbs Mol Ther 2004 10 386-398 10.1016/ j.ymthe.2004.05.004 15294185
44. Saivin S Houin G Clinical pharmacokinetics of doxycycline and minocycline Clin Pharmacokinet 1988 15 355-366 3072140
45. Porter WP Bitar YS Strandberg JD Charache PC Absence of therapeutic blood concentrations of tetracycline in rats after administration in drinking water Lab Anim Sci 1985 35 71-75 4039013
46. Percy DH Black WD Pharmacokinetics of tetracycline in the domestic rabbit following intravenous or oral administration Can J Vet Res 1988 52 5-11 1255391 3349401
47. Chernajovsky Y Systemic gene therapy for arthritis Drugs Today (Barc) 1999 35 361-377 12973439
48. Croxford JL Triantaphyllopoulos KA Neve RM Feldmann M Chernajovsky Y Baker D Gene therapy for chronic relapsing experimental allergic encephalomyelitis using cells expressing a novel soluble p75 dimeric TNF receptor J Immunol 2000 164 2776-2781 10679120
49. Jit M Henderson B Stevens M Seymour RM TNF-alpha neutralization in cytokine-driven diseases: A mathematical model to account for therapeutic success in rheumatoid arthritis but therapeutic failure in systemic inflammatory response syndrome Rheumatology (Oxford) 2005 44 323-331 10.1093/rheumatology/keh491 15585509
50. Chernajovsky Y Annenkov A Herman C Triantaphyllopoulos K Gould D Dreja H Moyes SP Croxford JL Mageed RA Podhajcer OL Gene therapy for rheumatoid arthritis. Theoretical considerations Drugs Aging 1998 12 29-41 10.2165/ 00002512-199812010-00004 9467685